Adamas Pharmaceuticals Inc. (ADMS) 16.98 $ADMS
Adamas Pharmaceuticals' Phase 2/3 Clinical Study Published in Movement Disorders
GlobeNewswire - Mon Feb 09, 3:01PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results from its Phase 2/3 clinical study of ADS-5102 (EASED) have been published in the online issue of the peer-reviewed journal Movement Disorders. ADS-5102 is initially being developed by Adamas for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a long-acting, extended-release capsule formulation of amantadine HCl administered once daily at bedtime.
ADMS: 16.98 (+0.03)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Direction of Market Influences: New Coverage of Acorda, Acura Pharmaceuticals, Adamas, Adamis and Addus HomeCare
PR Newswire - Wed Jan 14, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), Acura Pharmaceuticals (NASDAQ: ACUR), Adamas (NASDAQ: ADMS), Adamis (NASDAQ: ADMP), and Addus HomeCare (NASDAQ: ADUS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADMS: 16.98 (+0.03), ADUS: 21.57 (+0.18), ADMP: 6.50 (-0.01), ACOR: 36.14 (-0.51), ACUR: 0.55 (+0.01)
Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers
GlobeNewswire - Sun Jan 11, 6:00PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today provided a recap of its 2014 achievements and a preview of its near-term priorities. Adamas, which develops new treatments for neurological disorders, utilizes its technology platform to improve the pharmacokinetic profiles of approved drugs, alone and in fixed-dose combinations. The company's diversified business model includes forming partnerships to improve existing brands and developing wholly owned products. Its partnership to improve existing brands, which is currently focused on Alzheimer's disease, is with Forest Laboratories, a subsidiary of Actavis plc. Adamas' wholly owned product portfolio includes ADS-5102, now in late-stage clinical development for levodopa-induced dyskinesia (LID), a movement disorder associated with Parkinson's disease.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals wins USD30m milestone payment from Actavis for Namzaric
M2 - Fri Jan 09, 6:25AM CST
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) revealed on Thursday the receipt of USD30m milestone payment from Forest Laboratories Holdings, a subsidiary of Actavis.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas earns milestone from Actavis
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 3:19PM CST
ACT: 285.37 (+3.71), ADMS: 16.98 (+0.03)
Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis
GlobeNewswire - Thu Jan 08, 3:06PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today that it has received a $30 million milestone payment from Forest Laboratories Holdings Limited, a subsidiary of Actavis plc, based on the recent FDA approval of Namzaric(TM), formerly known as MDX-8704. Adamas developed a fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor) initially, and Namzaric is the first and only such fixed-dose combination approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric is covered by multiple Adamas US patents that extend up to 2029.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 03, 10:16AM CST
Source: StockMonkeys.com via Flickr. It's been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead's share price tied to the approval of AbbVie 's Viekira Pak and...
GILD: 101.90 (+1.10), ADMS: 16.98 (+0.03), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44), PDLI: 7.28 (+0.03)
Actavis' Alzheimer's Drug Approved; Bystolic Gets CRL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 12:20PM CST
While the FDA has issued a complete response letter (CRL) for Actavis' (ACT) hypertension treatment, it has given its approval for the company's Alzheimer???s drug.
ACT: 285.37 (+3.71), ADMS: 16.98 (+0.03), AKRX: 47.28 (-0.25), BIOD: 1.38 (-0.14)
Company News for December 26, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 9:10AM CST
Companies in the News are: CALM,ANFI,ADMS,BDSI
BDSI: 14.92 (+0.93), CALM: 35.73 (-0.42), ADMS: 16.98 (+0.03), ANFI: 8.84 (-0.42)
Adamas Pharmaceuticals (ADMS) Jumps: Stock Gains 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 8:25AM CST
Adamas Pharmaceuticals (ADMS) was a big mover last session, with shares rising nearly 10% on the day.
AKRX: 47.28 (-0.25), ADMS: 16.98 (+0.03)
Direction of Market Influences: New Coverage on Navigator Holdings, Adamas, Lindsay, Brookfield Residential and Las Vegas Sands
PR Newswire - Fri Dec 26, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Navigator Holdings (NYSE: NVGS), Adamas (NASDAQ: ADMS), Lindsay (NYSE: LNN), Brookfield Residential (NYSE: BRP), and Las Vegas Sands (NYSE: LVS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
NVGS: 17.48 (-0.06), LNN: 88.94 (-0.02), BRP: 24.17 (+0.01), ADMS: 16.98 (+0.03), LVS: 60.43 (+1.71)
Taser and Walgreen are big market movers
AP - Wed Dec 24, 12:37PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
RIG: 19.05 (+0.42), BRP: 24.17 (+0.01), ADMS: 16.98 (+0.03), TASR: 26.96 (-0.42), WAG: 76.05 (-0.49)
Market News: Adamas Pharmaceuticals, Virgin America, CalAmp
at The Street - Wed Dec 24, 12:21PM CST
The stock markets in the United States continue to advance with that Russell 2000 close to reaching a record level today. Sign up for our free daily newsletter Yesterday, the Dow Jones Industrial Aver...
VA: 34.79 (+0.93), CAMP: 18.55 (+0.07), ADMS: 16.98 (+0.03)
Premarket Gainers / Losers as of 9:10 ET
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 8:12AM CST
NVGS: 17.48 (-0.06), ACHN: 10.89 (-0.20), ADMS: 16.98 (+0.03), DGLY: 11.50 (-0.40)
FDA clears Adamas Alzheimer's drug
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 7:52AM CST
ACT: 285.37 (+3.71), ADMS: 16.98 (+0.03)
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
PR Newswire - Wed Dec 24, 7:00AM CST
Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
ACT: 285.37 (+3.71), ADMS: 16.98 (+0.03)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), TEVA: 56.77 (-0.58), ACOR: 36.14 (-0.51), PRTA: 22.89 (+0.13), NDRM: 10.76 (+0.22)
Adamas Pharmaceuticals wins six additional US patents for amantadine HCl
M2 - Wed Dec 03, 8:26AM CST
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday that it has received six additional patents in the US, bringing the total number of issued patents for amantadine-based controlled-release products to nine, with 12 more applications pending.
ADMS: 16.98 (+0.03)
Adamas Pharmaceuticals Issued Six Additional U.S. Patents
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced the issuance of six additional US patents (US 8,889,740; US 8,895,614; US 8,895,615; US 8,895,616; US 8,895,617 and US 8,895,618), bringing the total number of issued patents for amantadine-based controlled-release products owned by Adamas to nine, with 12 more applications pending. The newly issued patents include both composition of matter claims and claims covering methods for treatment of neurological diseases, including Parkinson's disease, related to the pharmacokinetic profile of amantadine HCl.
ADMS: 16.98 (+0.03)
Adamas Pharmaceuticals' Phase 2/3 Clinical Study Published in Movement Disorders
GlobeNewswire - Mon Feb 09, 3:01PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that results from its Phase 2/3 clinical study of ADS-5102 (EASED) have been published in the online issue of the peer-reviewed journal Movement Disorders. ADS-5102 is initially being developed by Adamas for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a long-acting, extended-release capsule formulation of amantadine HCl administered once daily at bedtime.
ADMS: 16.98 (+0.03)
Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), ACOR: 36.14 (-0.51), NDRM: 10.76 (+0.22)
Direction of Market Influences: New Coverage of Acorda, Acura Pharmaceuticals, Adamas, Adamis and Addus HomeCare
PR Newswire - Wed Jan 14, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), Acura Pharmaceuticals (NASDAQ: ACUR), Adamas (NASDAQ: ADMS), Adamis (NASDAQ: ADMP), and Addus HomeCare (NASDAQ: ADUS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADMS: 16.98 (+0.03), ADUS: 21.57 (+0.18), ADMP: 6.50 (-0.01), ACOR: 36.14 (-0.51), ACUR: 0.55 (+0.01)
Adamas Pharmaceuticals Provides Review of 2014 and Previews Upcoming Business Drivers
GlobeNewswire - Sun Jan 11, 6:00PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today provided a recap of its 2014 achievements and a preview of its near-term priorities. Adamas, which develops new treatments for neurological disorders, utilizes its technology platform to improve the pharmacokinetic profiles of approved drugs, alone and in fixed-dose combinations. The company's diversified business model includes forming partnerships to improve existing brands and developing wholly owned products. Its partnership to improve existing brands, which is currently focused on Alzheimer's disease, is with Forest Laboratories, a subsidiary of Actavis plc. Adamas' wholly owned product portfolio includes ADS-5102, now in late-stage clinical development for levodopa-induced dyskinesia (LID), a movement disorder associated with Parkinson's disease.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals wins USD30m milestone payment from Actavis for Namzaric
M2 - Fri Jan 09, 6:25AM CST
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) revealed on Thursday the receipt of USD30m milestone payment from Forest Laboratories Holdings, a subsidiary of Actavis.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
Adamas earns milestone from Actavis
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 3:19PM CST
ACT: 285.37 (+3.71), ADMS: 16.98 (+0.03)
Adamas Pharmaceuticals Receives $30 Million Milestone Payment From Actavis
GlobeNewswire - Thu Jan 08, 3:06PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced today that it has received a $30 million milestone payment from Forest Laboratories Holdings Limited, a subsidiary of Actavis plc, based on the recent FDA approval of Namzaric(TM), formerly known as MDX-8704. Adamas developed a fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor) initially, and Namzaric is the first and only such fixed-dose combination approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric is covered by multiple Adamas US patents that extend up to 2029.
ADMS: 16.98 (+0.03), FRX: 99.00 (-0.77)
3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 03, 10:16AM CST
Source: StockMonkeys.com via Flickr. It's been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead's share price tied to the approval of AbbVie 's Viekira Pak and...
GILD: 101.90 (+1.10), ADMS: 16.98 (+0.03), ABBV: 58.05 (+1.00), ENTA: 33.30 (-0.44), PDLI: 7.28 (+0.03)
Actavis' Alzheimer's Drug Approved; Bystolic Gets CRL - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 12:20PM CST
While the FDA has issued a complete response letter (CRL) for Actavis' (ACT) hypertension treatment, it has given its approval for the company's Alzheimer???s drug.
ACT: 285.37 (+3.71), ADMS: 16.98 (+0.03), AKRX: 47.28 (-0.25), BIOD: 1.38 (-0.14)
Company News for December 26, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 9:10AM CST
Companies in the News are: CALM,ANFI,ADMS,BDSI
BDSI: 14.92 (+0.93), CALM: 35.73 (-0.42), ADMS: 16.98 (+0.03), ANFI: 8.84 (-0.42)
Adamas Pharmaceuticals (ADMS) Jumps: Stock Gains 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 8:25AM CST
Adamas Pharmaceuticals (ADMS) was a big mover last session, with shares rising nearly 10% on the day.
AKRX: 47.28 (-0.25), ADMS: 16.98 (+0.03)
Direction of Market Influences: New Coverage on Navigator Holdings, Adamas, Lindsay, Brookfield Residential and Las Vegas Sands
PR Newswire - Fri Dec 26, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Navigator Holdings (NYSE: NVGS), Adamas (NASDAQ: ADMS), Lindsay (NYSE: LNN), Brookfield Residential (NYSE: BRP), and Las Vegas Sands (NYSE: LVS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
NVGS: 17.48 (-0.06), LNN: 88.94 (-0.02), BRP: 24.17 (+0.01), ADMS: 16.98 (+0.03), LVS: 60.43 (+1.71)
Taser and Walgreen are big market movers
AP - Wed Dec 24, 12:37PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
RIG: 19.05 (+0.42), BRP: 24.17 (+0.01), ADMS: 16.98 (+0.03), TASR: 26.96 (-0.42), WAG: 76.05 (-0.49)
Market News: Adamas Pharmaceuticals, Virgin America, CalAmp
at The Street - Wed Dec 24, 12:21PM CST
The stock markets in the United States continue to advance with that Russell 2000 close to reaching a record level today. Sign up for our free daily newsletter Yesterday, the Dow Jones Industrial Aver...
VA: 34.79 (+0.93), CAMP: 18.55 (+0.07), ADMS: 16.98 (+0.03)
Premarket Gainers / Losers as of 9:10 ET
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 8:12AM CST
NVGS: 17.48 (-0.06), ACHN: 10.89 (-0.20), ADMS: 16.98 (+0.03), DGLY: 11.50 (-0.40)
FDA clears Adamas Alzheimer's drug
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 7:52AM CST
ACT: 285.37 (+3.71), ADMS: 16.98 (+0.03)
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
PR Newswire - Wed Dec 24, 7:00AM CST
Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
ACT: 285.37 (+3.71), ADMS: 16.98 (+0.03)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 39.51 (+0.69), ADMS: 16.98 (+0.03), TEVA: 56.77 (-0.58), ACOR: 36.14 (-0.51), PRTA: 22.89 (+0.13), NDRM: 10.76 (+0.22)
Adamas Pharmaceuticals wins six additional US patents for amantadine HCl
M2 - Wed Dec 03, 8:26AM CST
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday that it has received six additional patents in the US, bringing the total number of issued patents for amantadine-based controlled-release products to nine, with 12 more applications pending.
ADMS: 16.98 (+0.03)
Adamas Pharmaceuticals Issued Six Additional U.S. Patents
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced the issuance of six additional US patents (US 8,889,740; US 8,895,614; US 8,895,615; US 8,895,616; US 8,895,617 and US 8,895,618), bringing the total number of issued patents for amantadine-based controlled-release products owned by Adamas to nine, with 12 more applications pending. The newly issued patents include both composition of matter claims and claims covering methods for treatment of neurological diseases, including Parkinson's disease, related to the pharmacokinetic profile of amantadine HCl.
ADMS: 16.98 (+0.03)
